NL2030011B1 - Prevention or treatment of hepatic steatosis - Google Patents

Prevention or treatment of hepatic steatosis Download PDF

Info

Publication number
NL2030011B1
NL2030011B1 NL2030011A NL2030011A NL2030011B1 NL 2030011 B1 NL2030011 B1 NL 2030011B1 NL 2030011 A NL2030011 A NL 2030011A NL 2030011 A NL2030011 A NL 2030011A NL 2030011 B1 NL2030011 B1 NL 2030011B1
Authority
NL
Netherlands
Prior art keywords
relative
anaerobutyricum
soehngenii
species
use according
Prior art date
Application number
NL2030011A
Other languages
English (en)
Dutch (nl)
Inventor
G Holleboom A
Meindert De Vos Willem
Nieuwdorp Max
Original Assignee
Caelus Pharmaceuticals B V
Acad Medisch Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caelus Pharmaceuticals B V, Acad Medisch Ct filed Critical Caelus Pharmaceuticals B V
Priority to NL2030011A priority Critical patent/NL2030011B1/en
Priority to EP22823493.6A priority patent/EP4440588A1/en
Priority to JP2024533245A priority patent/JP2024545441A/ja
Priority to US18/713,999 priority patent/US20250025517A1/en
Priority to CN202280079735.0A priority patent/CN118660712A/zh
Priority to PCT/EP2022/083885 priority patent/WO2023099579A1/en
Priority to TW111146093A priority patent/TW202332457A/zh
Application granted granted Critical
Publication of NL2030011B1 publication Critical patent/NL2030011B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NL2030011A 2021-12-03 2021-12-03 Prevention or treatment of hepatic steatosis NL2030011B1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NL2030011A NL2030011B1 (en) 2021-12-03 2021-12-03 Prevention or treatment of hepatic steatosis
EP22823493.6A EP4440588A1 (en) 2021-12-03 2022-11-30 Prevention or treatment of hepatic steatosis
JP2024533245A JP2024545441A (ja) 2021-12-03 2022-11-30 脂肪肝の予防、及び治療
US18/713,999 US20250025517A1 (en) 2021-12-03 2022-11-30 Prevention or treatment of hepatic steatosis
CN202280079735.0A CN118660712A (zh) 2021-12-03 2022-11-30 肝脂肪变性的预防或治疗
PCT/EP2022/083885 WO2023099579A1 (en) 2021-12-03 2022-11-30 Prevention or treatment of hepatic steatosis
TW111146093A TW202332457A (zh) 2021-12-03 2022-12-01 肝脂肪變性之預防或治療

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2030011A NL2030011B1 (en) 2021-12-03 2021-12-03 Prevention or treatment of hepatic steatosis

Publications (1)

Publication Number Publication Date
NL2030011B1 true NL2030011B1 (en) 2023-06-20

Family

ID=80448857

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2030011A NL2030011B1 (en) 2021-12-03 2021-12-03 Prevention or treatment of hepatic steatosis

Country Status (7)

Country Link
US (1) US20250025517A1 (enExample)
EP (1) EP4440588A1 (enExample)
JP (1) JP2024545441A (enExample)
CN (1) CN118660712A (enExample)
NL (1) NL2030011B1 (enExample)
TW (1) TW202332457A (enExample)
WO (1) WO2023099579A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025077370A1 (zh) * 2023-10-12 2025-04-17 雷文虎克生物技术股份有限公司 艾克曼嗜黏蛋白菌及其用于预防非酒精性脂肪肝炎的用途
WO2025229145A1 (en) 2024-05-02 2025-11-06 Stichting Amsterdam UMC Desulfovibrio piger species for prevention or treatment of hepatic steatosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020236979A1 (en) * 2019-05-21 2020-11-26 Pendulum Therapeutics, Inc. Methods and compositions for treating liver disorders
WO2021204719A1 (en) 2020-04-07 2021-10-14 Wholefiber Holding B.V. Particles comprising inulin for use as medicament or supplement

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020236979A1 (en) * 2019-05-21 2020-11-26 Pendulum Therapeutics, Inc. Methods and compositions for treating liver disorders
WO2021204719A1 (en) 2020-04-07 2021-10-14 Wholefiber Holding B.V. Particles comprising inulin for use as medicament or supplement

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS", 1993, ACADEMIC PRESS
"COMPUTER ANALYSIS OF SEQUENCE DATA", 1994, ACADEMIC PRESS
"NCBI", Database accession no. NR152695
"SEQUENCE ANALYSIS PRIMER", 1991, M STOCKTON PRESS
APPL ENVIRON MICROBIOL., vol. 86, no. 7, 18 March 2020 (2020-03-18), pages e03004 - 19
ATSCHUL, S. F. ET AL., J. MOLEC. BIOL., vol. 215, 1990, pages 403
BOTTACINI ET AL., J BACTERIOL, vol. 193, 2011, pages 6387 - 6388
CARILLO, H.LIPTON, D., SIAM J. APPLIED MATH, vol. 48, 1988, pages 1073
CARILLO, H.LIPTON, D.SIAM J., APPLIED MATH, vol. 48, 1988, pages 1073
CHIANG, LIVER RES, vol. 1, no. 1, June 2017 (2017-06-01), pages 3 - 9
COLLADO ET AL., APPL ENVIRON MICROBIOL, vol. 73, no. 23, December 2007 (2007-12-01), pages 7767 - 70
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, no. 1, 1984, pages 387
GILIJAMSE PIM W. ET AL: "Treatment with Anaerobutyricum soehngenii: a pilot study of safety and dose-response effects on glucose metabolism in human subjects with metabolic syndrome", NPJ BIOFILMS AND MICROBIOMES, vol. 6, no. 1, 1 December 2020 (2020-12-01), XP055879874, Retrieved from the Internet <URL:https://www.nature.com/articles/s41522-020-0127-0.pdf> DOI: 10.1038/s41522-020-0127-0 *
LISE SOFIE ET AL., TRANSFUSION AND APHERESIS SCIENCE, vol. 58, 2019, pages 113 - 116
SHETTY ET AL., INT J SYST EVOL MICROBIOL., vol. 68, no. 12, December 2018 (2018-12-01), pages 3741 - 3746
SHETTY SUDARSHAN A. ET AL: "Reclassification of Eubacterium hallii as Anaerobutyricum hallii gen. nov., comb. nov., and description of Anaerobutyricum soehngenii sp. nov., a butyrate and propionate-producing bacterium from infant faeces", INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, vol. 68, no. 12, 1 December 2018 (2018-12-01), GB, pages 3741 - 3746, XP055931086, ISSN: 1466-5026, DOI: 10.1099/ijsem.0.003041 *
SOLANKI ET AL., BIOMED RES. INT., 2013
T. ESLAMPARAST ET AL: "Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 99, no. 3, 8 January 2014 (2014-01-08), pages 535 - 542, XP055432715, ISSN: 0002-9165, DOI: 10.3945/ajcn.113.068890 *
VON HEINJE, G.: "SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY", 1987, ACADEMIC PRESS
WITJES, HEPATOLOGY COMMUNICATIONS, vol. 4, no. 11, 2020

Also Published As

Publication number Publication date
US20250025517A1 (en) 2025-01-23
WO2023099579A1 (en) 2023-06-08
EP4440588A1 (en) 2024-10-09
CN118660712A (zh) 2024-09-17
TW202332457A (zh) 2023-08-16
JP2024545441A (ja) 2024-12-06

Similar Documents

Publication Publication Date Title
CN105434476B (zh) 一种脆弱拟杆菌在预防和/或治疗炎症性肠病中的应用
EP3709978B1 (en) Pharmaceutical oral formulation comrpsing bacteria
EP2650002A1 (en) Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies
JP2006522766A (ja) シンビオティックな組み合わせ
EP3368053A1 (en) Faecalibacterium prausnitzii and desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
JP2022547330A (ja) 自閉症スペクトラム障害を治療するための組成物および方法
WO2025246510A1 (zh) 一株长双歧杆菌长亚种及其在预防、缓解、调节或治疗脂代谢相关疾病中的应用
CN108721337A (zh) 一种预防肿瘤化疗肠道毒性的微生物菌剂
JP2021524751A (ja) 組成物及びその使用
US20250025517A1 (en) Prevention or treatment of hepatic steatosis
KR101238836B1 (ko) 혼합 유산균을 포함하는 비만 또는 비만 관련 질환 치료 또는 예방용 약제학적 조성물 또는 식품 조성물
JP2012180288A (ja) 抗菌剤
JP2025521181A (ja) ビタミンＣ及びビフィドバクテリウム・アニマリス亜種ラクティス（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ａｎｉｍａｌｉｓ ｓｓｐ．ｌａｃｔｉｓ）を含む組み合わせ
Pande et al. Prospectus of probiotics in modern age diseases
CN111132684A (zh) 作为生物治疗药物的血孪生球菌
KR20200037292A (ko) 생물학적 치료제로서 스트렙토코크스 아루스트랄리스
CN115466689A (zh) 用于预防和/或治疗代谢类疾病的益生菌组合物及其应用
WO2021142353A1 (en) Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
WO2021142358A1 (en) Compositions and methods for treating hepatic encephalopathy (he)
TW201336989A (zh) 雙歧桿菌ｃｅｃｔ７７６５及彼於預防及／或治療過重、肥胖症及相關病徵之用途
JP2025519400A (ja) ビタミンＣ及びラクトバチルス・ラムノサス（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ）を含む組み合わせ
WO2025229145A1 (en) Desulfovibrio piger species for prevention or treatment of hepatic steatosis
JP2025519401A (ja) ビタミンＢ２及びラクトバチルス・ラムノサス（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ）を含む組み合わせ
WO2023237680A1 (en) Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis
WO2023237673A1 (en) Combinations comprising vitamin c and bifidobacterium animalis ssp. lactis

Legal Events

Date Code Title Description
PD Change of ownership

Owner name: STICHTING AMSTERDAM UMC; NL

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: CAELUS PHARMACEUTICALS B.V.

Effective date: 20240223

PD Change of ownership

Owner name: STICHTING AMSTERDAM UMC; NL

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: STICHTING AMSTERDAM UMC

Effective date: 20251209